28097508|t|Preparation and evaluation of biopolymeric nanoparticles as drug delivery system in effective treatment of rheumatoid arthritis
28097508|a|The study purposes to evaluate nanocrystalline biopolymeric nanoparticles encapsulating methotrexate and dexamethasone with high biocompatibility, enhanced therapeutic efficacy and reduced toxicity. Chitosan nanoparticles were prepared by ionic gelation, and Methotrexate (MTX) and Dexamethasone (DEX) were loaded during the preparation and screened for their in vitro efficacy in HEK and RAW264.7 cells, ex vivo and in vivo efficacy. FTIR confirmed the involvement of phosphoric group of sTPP with amine groups of chitosan and also role of hydrogen bonding involved in the preparation of MTXCHNP and DEXCHNP. Controlled release patterns coupled with diffusion of drug were observed in two different buffers (PBS) at pH 7.4 and pH 5.8. The IC50 for MTXCHNP for HEK was 26.1 μg/ml and 7.7 μg/ml for RAW 264.7 cells. In DEXCHNP, the IC50 was 20.12 μg/ml for HEK and 7.37 μg/ml for RAW264.7 cells. Enhanced uptake of FITC - CHNP by RAW cells indicated internalization of nanoparticles by phagocytosis. The enhanced release of drug at lower pH justified increased cytotoxicity. Negligible ex-vivo hemolysis indicated the higher biocompatibility of the nanoparticles. (99m)Tc - CHNP exhibited maximum absorption in blood circulation in 3 h, followed by hepatic metabolism and renal clearance. Higher in-vivo anti-arthritic activity and antioxidant activity was observed post-intraperitoneal (i.p.) injections by both MTXCHNP and DEXCHNP when compared to MTX (0.75 mg/Kg by i.p. route) and DEX (0.2 mg/Kg/ i.p. /daily) per se. The nanocrystalline biopolymeric nanoparticles were stable, biocompatible and have potential to be administered through i.p. route with minimal toxicity and high efficacy.
28097508	0	11	Preparation	T052	C1521827
28097508	16	26	evaluation	T058	C0220825
28097508	30	42	biopolymeric	T116,T123	C0005554
28097508	43	56	nanoparticles	T073	C1450054
28097508	60	80	drug delivery system	T074	C0085104
28097508	94	103	treatment	T061	C0087111
28097508	107	127	rheumatoid arthritis	T047	C0003873
28097508	150	158	evaluate	T058	C0220825
28097508	159	174	nanocrystalline	T073	C1721058
28097508	175	187	biopolymeric	T116,T123	C0005554
28097508	188	201	nanoparticles	T073	C1450054
28097508	202	215	encapsulating	T080	C0205223
28097508	216	228	methotrexate	T109,T121	C0025677
28097508	233	246	dexamethasone	T109,T121	C0011777
28097508	257	273	biocompatibility	T044	C0596177
28097508	284	304	therapeutic efficacy	T080	C2348767
28097508	317	325	toxicity	T080	C0040539
28097508	327	335	Chitosan	T109,T121	C0162969
28097508	336	349	nanoparticles	T073	C1450054
28097508	355	363	prepared	T033	C4082130
28097508	367	381	ionic gelation	T067	C1522240
28097508	387	399	Methotrexate	T109,T121	C0025677
28097508	401	404	MTX	T109,T121	C0025677
28097508	410	423	Dexamethasone	T109,T121	C0011777
28097508	425	428	DEX	T109,T121	C0011777
28097508	435	441	loaded	T052	C1708715
28097508	453	464	preparation	T052	C1521827
28097508	469	477	screened	T059	C0373483
28097508	488	496	in vitro	T062	C0681828
28097508	509	512	HEK	T025	C2936239
28097508	517	531	RAW264.7 cells	T025	C4042840
28097508	533	540	ex vivo	T062	C0242481
28097508	545	552	in vivo	T062	C0681829
28097508	563	567	FTIR	T062	C0206055
28097508	597	613	phosphoric group	T104	C1254350
28097508	617	621	sTPP	T121,T130,T197	C0301008
28097508	627	639	amine groups	T109	C1879694
28097508	643	651	chitosan	T109,T121	C0162969
28097508	669	685	hydrogen bonding	T070	C0020276
28097508	702	713	preparation	T052	C1521827
28097508	717	724	MTXCHNP	T073	C1450054
28097508	729	736	DEXCHNP	T073	C1450054
28097508	738	756	Controlled release	T079	C0868939
28097508	779	788	diffusion	T070	C0012222
28097508	792	796	drug	T121	C1254351
28097508	828	835	buffers	T121,T130	C0006353
28097508	837	840	PBS	T121,T130	C0991865
28097508	845	847	pH	T081	C0020283
28097508	856	858	pH	T081	C0020283
28097508	868	872	IC50	T081	C0600495
28097508	877	884	MTXCHNP	T073	C1450054
28097508	889	892	HEK	T025	C2936239
28097508	926	941	RAW 264.7 cells	T025	C4042840
28097508	946	953	DEXCHNP	T073	C1450054
28097508	959	963	IC50	T081	C0600495
28097508	984	987	HEK	T025	C2936239
28097508	1007	1021	RAW264.7 cells	T025	C4042840
28097508	1049	1053	CHNP	T073	C1450054
28097508	1057	1066	RAW cells	T025	C0007634
28097508	1077	1092	internalization	T041	C0871786
28097508	1096	1109	nanoparticles	T073	C1450054
28097508	1113	1125	phagocytosis	T043	C0031308
28097508	1151	1155	drug	T121	C1254351
28097508	1165	1167	pH	T081	C0020283
28097508	1188	1200	cytotoxicity	T049	C0596402
28097508	1213	1220	ex-vivo	T062	C0242481
28097508	1221	1230	hemolysis	T034	C2945560
28097508	1252	1268	biocompatibility	T044	C0596177
28097508	1276	1289	nanoparticles	T073	C1450054
28097508	1291	1298	(99m)Tc	T130	C0303611
28097508	1301	1305	CHNP	T073	C1450054
28097508	1324	1334	absorption	T067	C2347023
28097508	1338	1355	blood circulation	T039	C0005775
28097508	1376	1394	hepatic metabolism	T042	C1373178
28097508	1399	1414	renal clearance	T042	C0232813
28097508	1423	1430	in-vivo	T062	C0681829
28097508	1431	1454	anti-arthritic activity	T033	C0243095
28097508	1459	1479	antioxidant activity	T044	C1148564
28097508	1493	1531	post-intraperitoneal (i.p.) injections	T061	C0021493
28097508	1540	1547	MTXCHNP	T073	C1450054
28097508	1552	1559	DEXCHNP	T073	C1450054
28097508	1577	1580	MTX	T109,T121	C0025677
28097508	1596	1606	i.p. route	T169	C1522583
28097508	1612	1615	DEX	T109,T121	C0011777
28097508	1628	1632	i.p.	T169	C1522583
28097508	1653	1668	nanocrystalline	T073	C1721058
28097508	1669	1681	biopolymeric	T116,T123	C0005554
28097508	1682	1695	nanoparticles	T073	C1450054
28097508	1701	1707	stable	T080	C0205360
28097508	1709	1722	biocompatible	T044	C0596177
28097508	1732	1741	potential	T080	C3245505
28097508	1769	1779	i.p. route	T169	C1522583
28097508	1793	1801	toxicity	T080	C0040539
28097508	1811	1819	efficacy	T080	C1280519